Seattle, WANCT07564401Now EnrollingIRB Ready

Extensive-stage Small Cell Lung Cancer (ES-SCLC) Clinical Trial in Seattle, WA

Access cutting-edge extensive-stage small cell lung cancer (es-sclc) treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access extensive-stage small cell lung cancer (es-sclc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related extensive-stage small cell lung cancer (es-sclc) treatment provided free

Apply for This Seattle Location

Check if you qualify for this extensive-stage small cell lung cancer (es-sclc) clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Extensive-stage Small Cell Lung Cancer (ES-SCLC) Study in Seattle

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Phase I: Patients with ES-SCLC and disease progression after one or more chemotherapy regimens (that included a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor) according to the local SOC (2L+), unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, according to the investigator's judgement. Prior DLL3 (Delta-like ligand 3) targeted therapy is allowed.
Phase II: Patients with ES-SCLC who have received a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor according to local standard of care, unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, as determined by the investigator's judgment. Prior DLL-3 targeted therapy is not allowed.
Male or female patients must be ≥ 18 years of age.
Histologically or cytologically confirmed small cell lung cancer (SCLC).
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients must have an archival tumor tissue available, collected within 6 months prior to screening. If an archival tumor sample, collected within 6 months prior to screening, is not available, patients must be willing to undergo a new tumor biopsy at screening; , however this specimen need not be collected prior to scheduling leukapheresis. If a new biopsy is not medically feasible, exceptions may be considered after documented discussion with the Novartis medical monitor.
Patient must be deemed suitable by the investigator to undergo the lymphodepletion (LD) regimen.
Patient must have an apheresis product of non-mobilized cells accepted for manufacturing.

Exclusion Criteria

Prior administration of a genetically modified cellular product, including prior DLL3-targeted CAR-T cell therapy.
Unstable or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. Stable brain metastases may participate provided they meet the specific criteria.
Uncontrolled seizure disorder.
Clinically significant active infections, including Hepatitis B/C and Human Immunodeficiency Virus (HIV).
Has a known additional malignancy that is progressing or requires active treatment, with specific exceptions as defined in the study protocol.
History of prior solid organ transplant or allogenic hematopoietic cell transplant
Other significant pulmonary, cardiac, hepatic, renal or neurologic disease, parameters for which are defined in the study protocol.
Pregnant or nursing women. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07564401) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Extensive-stage Small Cell Lung Cancer (ES-SCLC) Treatment Options in Seattle, WA

If you're searching for extensive-stage small cell lung cancer (es-sclc) treatment options in Seattle, WA, this clinical trial (NCT07564401) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced extensive-stage small cell lung cancer (es-sclc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all extensive-stage small cell lung cancer (es-sclc) clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Seattle, WA

See all lung cancer clinical trials recruiting in Seattle — not just this study.

Browse Lung Cancer Trials in Seattle →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA